Quick Answer
CG Oncology, Inc. reported Diluted EPS of $2.08 per share (loss) for fiscal year 2025.
CG Oncology, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.08 | -47.5% |
| 2024 | -$1.41 | +91.0% |
| 2023 | -$15.65 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.57 | -90.0% | -5.6% |
| June 30, 2025 | -$0.54 | -92.9% | -20.0% |
| March 31, 2025 | -$0.45 | -25.0% | -50.0% |
| September 30, 2024 | -$0.30 | +92.5% | -7.1% |
| June 30, 2024 | -$0.28 | +92.9% | +22.2% |
| March 31, 2024 | -$0.36 | +88.8% | +91.0% |
| September 30, 2023 | -$4.00 | — | -1.8% |
| June 30, 2023 | -$3.93 | — | -22.0% |
- CG Oncology, Inc. showed a decrease of -47.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, CG Oncology, Inc.’s diluted eps has grown by 86.7% (from $15.65 per share (loss) to $2.08 per share (loss)).
- The most recent figure is from CG Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: